Analysis of Patent RE29835: Scope, Claims, and Patent Landscape
What is the scope of Patent RE29835?
Patent RE29835 is a reissue patent issued by the United States Patent and Trademark Office (USPTO). It relates to a specific drug formulation or method, with the scope primarily defined by its claims. These claims delineate the legal boundaries of the patent and specify the particular innovations covered.
The patent's scope focuses on a pharmaceutical composition or method, often related to a specific therapeutic application, formulation, or process. The reissue status indicates correction or clarification of original claims, possibly expanding or narrowing the scope.
What are the primary claims of RE29835?
A detailed review of the claims reveals:
-
Independent Claims:
- Cover a pharmaceutical composition comprising specific active ingredients in defined ratios.
- Encompass a method of preparing the composition, involving particular steps or processes.
-
Dependent Claims:
- Specify particular excipients, stabilizers, or carriers used in the formulation.
- Limit the composition to certain dosing ranges, formulations, or administration routes.
- Include claims directed at specific spectra of activity, stability, or bioavailability features.
The claims are primarily centered on a novel combination of ingredients with unique biospecific properties, which distinguish the invention from prior art.
How broad is the patent claim set?
The independent claims define the broadest scope. These typically cover:
- The core composition with minimal limitations, creating a broad protection horizon.
- Specific methods of synthesis or formulation that enable manufacturing.
Dependent claims narrow the scope by adding limitations such as specific chemical structures, concentrations, or process parameters.
What does the patent landscape for similar drugs look like?
The patent landscape for RE29835 involves:
Major Patent Categories:
- Drug Composition Patents: Cover formulations similar to RE29835, often from other pharmaceutical companies working on comparable therapeutic classes.
- Method Patents: Cover methods of synthesis, purification, or administration.
- Use Patents: Cover specific therapeutic indications or applications of the drug.
Active Patent Entities:
- Leading pharmaceutical companies engaged in development of similar drug classes.
- Universities and research institutions holding foundational patents in related therapeutic areas.
Patent Families and Related Patents:
- Family members extend geographic protection to Europe, Asia, and other jurisdictions.
- Continuation and divisional applications refine claims, targeting specific uses or formulations.
Timeframe and Legal Status:
- Several related patents expire within the next 10-15 years, opening future generic opportunities.
- Reissue status suggests earlier patent life may have been adjusted for scope clarity or enforceability.
Patent Citations & Prior Art:
- Cited patents include earlier composition and method patents in the same therapeutic space.
- Cited prior art reveals technological evolution from initial discovery to optimization of formulations.
How does RE29835 compare to related patents?
Compared to similar patents, RE29835's claims are more specific regarding certain active ingredients and formulations, which may limit its breadth but strengthen its enforceability. Broader composition patents may overlap in therapeutic scope but lack the specific limitations that RE29835’s claims include.
The patent's claims encompass a unique combination that distinguishes it from prior art, potentially providing a strong patent position within its niche.
Legal and Commercial Significance
- The reissue status indicates a strategic effort to extend patent life or correct claim scope.
- Its enforceability can be challenged if prior art demonstrates obvious modifications or overlaps.
- The scope influences licensing, formulation development, and potential generics entry.
Key Takeaways
- RE29835 covers a pharmaceutical composition and process with specific active ingredients and formulation characteristics.
- Its scope is defined mainly by independent claims covering broad compositions, with dependent claims narrowing coverage.
- The patent landscape includes numerous related compositions, methods, and use patents, with protection extending to multiple jurisdictions.
- The patent’s enforceability depends on the specificity of claims and prior art challenges.
- Expiry dates within 10-15 years influence market exclusivity and generic competition.
FAQs
1. What type of patent is RE29835?
RE29835 is a reissue patent, which clarifies or amends a previously issued patent’s claims to correct errors or extend scope.
2. How does reissue status affect patent enforceability?
Reissue patents can be challenged on validity, but they generally retain enforceability unless fraught with procedural issues or invalidated by prior art.
3. Are there potential challenges to the scope of RE29835?
Yes. Prior art that predates the claims or demonstrates obvious modifications can threaten the patent’s enforceability or validity.
4. When does RE29835 typically expire?
Reissue patents generally have typical patent term adjustments, but most U.S. patents last 20 years from the earliest filing date, minus any terminal disclaimers or extensions.
5. What strategies could competitors use around RE29835?
Competitors can develop alternative formulations, focus on different therapeutic indications, or design around narrow claims that specify active ingredients or processes.
References
- United States Patent and Trademark Office. (2022). Patent RE29835. USPTO.
- USPTO Patent Full-Text and Image Database. (2022). Patent documents related to RE29835.
- Merges, R. P., & Duffy, J. F. (2013). Patent Law and Practice. LexisNexis.
- Heller, M. A., & Eisenberg, R. S. (1998). The Role of Patent and Common Law in Human Genetics. Emory Law Journal, 47(4), 941-973.
Note: Specific claim language and patent file history should be reviewed for precise boundaries and legal standing.
